University of Calgary, Tom Baker Cancer Centre, Calgary, AB
Dr. Ruether is a medical oncologist at the TBCC who has worked in the GU program for 20 years.
His undergraduate training was done at the university of Calgary and medical school completed at the University of Alberta. Post graduate training in internal medicine, hematology and medical oncology was completed at the University of Calgary.
As the leader of the local and provincial GU program Dr Ruether has played an important role in bringing clinical research trials for patients with all stages of prostate cancer to Alberta. He is also responsible for the development of an educational program run through the prostate cancer center in Calgary for patients and their families dealing with a new diagnosis of prostate cancer.
Hack TF, Ruether JD, Weir LM, Grenier D, Degner LF. Promoting consultation recording practice in oncology: identification of critical implementation factors and determination of patient benefit. Psychooncology. 2013 Jun;22(6):1273-82.
Hovey RB, Cuthbertson KE, Birnie KA, Robinson JW, Thomas BC, Massfeller HF, Ruether JD, Scott C. The influence of distress on knowledge transfer for men newly diagnosed with prostate cancer. J Cancer Educ. 2012 Jun;27(3):540-5.
Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J. 2011 Dec;5(6):416-21.
Hack TF, Ruether JD, Pickles T, Bultz BD, Chateau D, & Degner LF. Behind closed doors II: Systematic analysis of prostate cancer patients’ primary treatment consultations with radiation oncologists and predictors of satisfaction with communication. Psycho-Oncology.May 6, 2011 doi:10.1002/pon.1984.
Scher H, Jia X, Chi K, De Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether JD, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G. Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology (epub ahead of print). Apr 11, 2011.
Hack TK, Carlson L, Butler L, Degner LF, Jakulj F, Pickles T, Ruether Dean J, Weir L. Facilitating the implementation of empirically valid interventions in psychosocial oncology and supportive care. Supportive Care Cancer (19) 1097-1105. doi: 10.1007/s00520-011-1159-z. Apr 2011.
Thomas F Hack, J Dean Ruether, Lorna M Weir, Debjani Grenier, & Lesley F Degner. Study protocol: Addressing evidence and context to facilitate transfer and uptake of consultation recording use in oncology: A knowledge translation implementation study. Implementation Science 2011, 6:20. doi:10.1186/1748-5908-6-20
Hotte S.J, Bjarnason G.A., Heng D.Y.C, Jewett M.A.S, Kapoor A, Kollmannsberger C, Maroun J, Mayhew L.A, North S, Reaume M.N, Ruether J.D, Soulieres D, Venner P.M, Winquist E.W, Wood L, Yong J.H.E, Saad F. Progression-free survival as a clinical trial endpoint in advanced renal carcinoma. Current Oncology, Volume 18 (2) ; S11-S19. 2011.
Steering Committee Members, Program Committee, Other Presenters and Participants, Ruether D. Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Update. Can Urol Assoc J. 3(3). Jun 2009.
Hack TF, Pickles T, Ruether JD, Weir L, Bultz BD, Degner LF. Behind closed doors: Systematic analysis of breast cancer consultation communication and predictors of satisfaction with communication. Psycho-Oncology. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/pon.1592. 2009.
Daniel Heng, Wanling Xie, Meredith M. Regan, Mark A. Warren, Ali Reza Golshayan, Chakshu Sahi, Bernie Eigl, Dean Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N. Chi, Christian Kollmannsberger, David F. McDermott, William K. Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. Journal of Clinical Oncology, 27(34), 5794-99. 2009.
Fred Saad, Dean Ruether, Scott Ernst, Scott North, Tina Cheng, Paul Perrotte, Pierre Karakiewicz and Eric Winquist. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int.;102(5):551-5. Jan 31, 2008.
Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol;26(11):1900-1, 2008.
Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD; ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer;112(2):326-30, 2008.
Saad F, Ruether D, Ernst S, North S, Cheng T, Perrotte P, Karakiewicz P, Winquist E; Canadian Uro-Oncology Group. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int.;102(5):551-5, 2008.